EFS according to ELN and subclassification of adverse karyotypes. (A) EFS after HSCT of all patients according to classification into intermediate II and adverse risk. (B-C) Adverse-risk patients are classified hierarchically into 3 groups: (1) patients with abnl(17p) AML, (2) patients without abnl(17p) but with −5/5q−, and (3) patients with neither abnl(17p) nor −5/5q−. (B) EFS of all patients and (C) EFS of patients who received transplants in first remission with a morphologically leukemia-free marrow.